Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens.
Haicheur N, Bismuth E, Bosset S, Adotevi O, Warnier G, Lacabanne V, Regnault A, Desaymard C, Amigorena S, Ricciardi-Castagnoli P, Goud B, Fridman WH, Johannes L, Tartour E. Haicheur N, et al. Among authors: adotevi o. J Immunol. 2000 Sep 15;165(6):3301-8. doi: 10.4049/jimmunol.165.6.3301. J Immunol. 2000. PMID: 10975847
Targeting two radiation-induced immunosuppressive pathways to improve the efficacy of normofractionated radiation therapy in a preclinical colorectal cancer model.
Boustani J, Lecoester B, Baude J, Latour C, Limagne E, Ladjohoulou R, Morgand V, Froidurot L, Ghiringhelli F, Truc G, Adotévi O, Mirjolet C. Boustani J, et al. Among authors: adotevi o. Int J Radiat Biol. 2024;100(6):912-921. doi: 10.1080/09553002.2024.2331115. Epub 2024 Mar 20. Int J Radiat Biol. 2024. PMID: 38506658
Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes.
Dalens L, Niogret J, Richard C, Chevrier S, Foucher P, Coudert B, Lagrange A, Favier L, Westeel V, Kim S, Adotevi O, Chapusot C, Martin L, Arnould L, Kaderbhai CG, Boidot R. Dalens L, et al. Among authors: adotevi o. Mol Cancer. 2023 Jul 29;22(1):120. doi: 10.1186/s12943-023-01829-4. Mol Cancer. 2023. PMID: 37516818 Free PMC article.
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).
Vienot A, Jacquin M, Rebucci-Peixoto M, Pureur D, Ghiringhelli F, Assenat E, Hammel P, Rosmorduc O, Stouvenot M, Allaire M, Bouattour M, Regnault H, Fratte S, Raymond E, Soularue E, Husson-Wetzel S, Di Martino V, Muller A, Clairet AL, Fagnoni-Legat C, Adotevi O, Meurisse A, Vernerey D, Borg C. Vienot A, et al. Among authors: adotevi o. BMC Cancer. 2023 Jul 29;23(1):710. doi: 10.1186/s12885-023-11065-0. BMC Cancer. 2023. PMID: 37516867 Free PMC article. Clinical Trial.
THBS1+ myeloid cells expand in SLD hepatocellular carcinoma and contribute to immunosuppression and unfavorable prognosis through TREM1.
Giraud J, Chalopin D, Ramel E, Boyer T, Zouine A, Derieppe MA, Larmonier N, Adotevi O, Le Bail B, Blanc JF, Laurent C, Chiche L, Derive M, Nikolski M, Saleh M. Giraud J, et al. Among authors: adotevi o. Cell Rep. 2024 Feb 27;43(2):113773. doi: 10.1016/j.celrep.2024.113773. Epub 2024 Feb 12. Cell Rep. 2024. PMID: 38350444 Free article.
Chemotherapy to potentiate the radiation-induced immune response.
Lecoester B, Wespiser M, Marguier A, Mirjolet C, Boustani J, Adotévi O. Lecoester B, et al. Among authors: adotevi o. Int Rev Cell Mol Biol. 2023;376:143-173. doi: 10.1016/bs.ircmb.2023.01.004. Epub 2023 Feb 11. Int Rev Cell Mol Biol. 2023. PMID: 36997268 Review.
111 results